JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Sanofi

Закрыт

51.62 4.07

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

51.44

Макс.

51.86

Ключевые показатели

By Trading Economics

Доход

2.1B

3.9B

Продажи

129M

11B

P/E

Средняя по отрасли

16.577

37.461

Прибыль на акцию

0.91

Дивидендная доходность

7.74

Рентабельность продаж

36.702

Сотрудники

82,878

EBITDA

-881M

1.9B

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+21.03% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

7.74%

2.33%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.4B

123B

Предыдущая цена открытия

47.55

Предыдущая цена закрытия

51.62

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Sanofi График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 окт. 2025 г., 08:29 UTC

Отчет

Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue -- Update

24 окт. 2025 г., 07:00 UTC

Отчет

Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance

1 окт. 2025 г., 08:54 UTC

Главные движущие силы рынка

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

4 сент. 2025 г., 08:58 UTC

Главные движущие силы рынка

Sanofi Shares Sink as Experimental Drug Results Disappoint

31 июл. 2025 г., 06:00 UTC

Отчет

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

24 окт. 2025 г., 08:21 UTC

Обсуждения рынка
Отчет

Sanofi Results Reflect Improved Efficiency, Should Ease Margin Worries -- Market Talk

24 окт. 2025 г., 07:56 UTC

Обсуждения рынка
Отчет

Sanofi's Dupixent Drives Growth, But Lantus Gains Set to Fade -- Market Talk

24 окт. 2025 г., 05:30 UTC

Отчет

Sanofi 3Q Adj EPS EUR2.91

24 окт. 2025 г., 05:30 UTC

Отчет

Sanofi Backs 2025 View

24 окт. 2025 г., 05:30 UTC

Отчет

Analysts Saw Sanofi 3Q Business Net Profit at EUR3.29B

24 окт. 2025 г., 05:30 UTC

Отчет

Sanofi 3Q Business Net Profit at EUR3.55B

24 окт. 2025 г., 05:30 UTC

Отчет

Analysts Saw Sanofi 3Q Adjusted EPS at EUR2.70

24 окт. 2025 г., 05:30 UTC

Отчет

Sanofi: Dupixent Sales Up 26% to EUR4.16B

24 окт. 2025 г., 05:30 UTC

Отчет

Sanofi 3Q Net Pft EUR2.80B

24 окт. 2025 г., 05:30 UTC

Отчет

Analysts Saw Sanofi 3Q Net Sales at EUR12.29B

24 окт. 2025 г., 05:30 UTC

Отчет

Sanofi 3Q Sales EUR12.43B

6 окт. 2025 г., 08:15 UTC

Обсуждения рынка

Sanofi's Profitability Stronger Than It Looks -- Market Talk

3 окт. 2025 г., 14:10 UTC

Обсуждения рынка

Sanofi Sales Could Miss Forecasts, With Adjusted Profit in Line -- Market Talk

1 окт. 2025 г., 07:53 UTC

Обсуждения рынка

Pfizer's U.S. Pricing Move Brings Clarity for Pharma Sector -- Market Talk

5 сент. 2025 г., 08:24 UTC

Обсуждения рынка

Sanofi's Eczema Drug Candidate Could Still Become a Blockbuster -- Market Talk

5 сент. 2025 г., 06:55 UTC

Обсуждения рынка

Sanofi Share Fall After Eczema Trial Results Looks Overdone -- Market Talk

6 авг. 2025 г., 05:02 UTC

Приобретения, слияния, поглощения

Sanofi Completes the Acquisition of Vigil Neuroscience

6 авг. 2025 г., 05:00 UTC

Приобретения, слияния, поглощения

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 авг. 2025 г., 13:16 UTC

Отчет

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 авг. 2025 г., 12:40 UTC

Отчет

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 июл. 2025 г., 08:15 UTC

Обсуждения рынка
Отчет

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 июл. 2025 г., 05:56 UTC

Обсуждения рынка
Отчет

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 июл. 2025 г., 05:30 UTC

Отчет

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 июл. 2025 г., 05:30 UTC

Отчет

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 июл. 2025 г., 05:30 UTC

Отчет

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

Сравнение c конкурентами

Изменение цены

Sanofi Прогноз

Целевая цена

By TipRanks

21.03% рост

Прогноз на 12 месяцев

Средняя 62.5 USD  21.03%

Максимум 67 USD

Минимум 58 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Sanofi на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

3 ratings

3

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

51.665 / 52.38Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat